RELEASE: PierianDx Announces Partnership with Cancer Genetics to Provide Comprehensive Precision Oncology Testing and Workflow Solution

PierianDx, the leading genomics technology company that enables precision medicine programs and molecular testing for healthcare organizations, announced today a partnership with Cancer Genetics, Inc. (CGI) (Nasdaq: CGIX) to provide a comprehensive precision oncology testing and workflow solution to enhance patient care. CGI is a leader in enabling precision medicine for oncology through molecular markers and diagnostics.

The partnership combines CGI’s Focus::NGS® offering, a suite of next generation sequencing (NGS) tests providing a comprehensive view of the patient genomic profile for both solid tumors and hematologic malignancies, with PierianDx’s integrated NGS workflow and analysis solution: Clinical Genomics WorkSpace™ (CGW), allowing for streamlined and accurate analysis, interpretation, and reporting.

“By partnering with PierianDx to offer a comprehensive solution for precision oncology, we will be able to guide a physician’s therapeutic strategy for each of their patients based on refined data from powerful genomic tests, thereby delivering on the potential of personalized medicine,” said John A. “Jay” Roberts, interim CEO for CGI. “The combined capabilities allow physicians to seamlessly link the genetic profile of each patient to approved therapies and clinical trials, enabling the potential for improved outcomes.”

“CGI’s suite of tests combined with PierianDx’s technology and services will help accelerate molecular diagnostics for cancer patients,” said Rakesh Nagarajan, PierianDx founder and CEO. “Fulfilling the promise of precision medicine requires this type of valuable partnerships.”

Nagarajan noted that the partnership will produce actionable clinical insights and reports for pathologists and oncologists utilizing both PierianDx interpretation services and CGW’s KnowledgeSpace™ which cultivates and curates billions of biomedical findings, expanding its intelligence with each use.

The KnowledgeSpace™ includes curated variant classification guidelines by the Association of Molecular Pathology (AMP), American Society of Clinical Oncology (ASCO), and the College of American Pathologists (CAP). PierianDx’s board-certified molecular pathologists and medical geneticists will further review cases to make assessments on medical meaningfulness of variants. This information will include recommended therapeutic options, more aggressive or conservative disease monitoring, as well as recommended clinical trials, each of which offered in the appropriate clinical context. The personnel reviewing the cases can also be available to participate in molecular tumor boards or to consult directly with the patient’s treating physician.

About Cancer Genetics

Cancer Genetics Inc. is a leader in enabling precision medicine in oncology from bench to bedside through the use of oncology biomarkers and molecular testing. CGI is developing a global footprint with locations in the US, India, China and Australia. We have established strong clinical research collaborations with major cancer centers such as Memorial Sloan Kettering, The Cleveland Clinic, Mayo Clinic, Keck School of Medicine at USC and the National Cancer Institute. The company offers a comprehensive range of laboratory services that provide critical genomic and biomarker information. Its state-of-the-art reference labs are CLIA-certified and CAP-accredited in the US and have licensure from several states including New York State. For more information, please visit or follow CGI at:

20 thoughts on “RELEASE: PierianDx Announces Partnership with Cancer Genetics to Provide Comprehensive Precision Oncology Testing and Workflow Solution

  1. Great post. I used to be checking constantly this blog and I am impressed! Very helpful information specially the ultimate phase 🙂 I maintain such info much. I used to be looking for this particular info for a long time. Thanks and good luck.

  2. I simply couldn’t depart your web site prior to suggesting that I extremely enjoyed the standard info a person supply for your visitors? Is gonna be again ceaselessly to investigate cross-check new posts.

  3. Somebody necessarily assist to make critically articles I would state. This is the first time I frequented your web page and thus far? I amazed with the research you made to make this actual submit incredible. Wonderful job!

  4. My brother recommended I might like this blog. He was totally right. This post actually made my day. You can not imagine just how much time I had spent for this info! Thanks!

  5. Hi there, i read your blog from time to time and i own a similar one and i was just curious if you get a lot of spam comments? If so how do you protect against it, any plugin or anything you can advise? I get so much lately it’s driving me mad so any assistance is very much appreciated.

  6. Thank you for sharing superb informations. Your site is so cool. I’m impressed by the details that you?¦ve on this website. It reveals how nicely you perceive this subject. Bookmarked this web page, will come back for extra articles. You, my pal, ROCK! I found just the information I already searched everywhere and just couldn’t come across. What a perfect site.

  7. excellent submit, very informative. I’m wondering why the other experts of this sector don’t understand this. You should proceed your writing. I am sure, you have a huge readers’ base already!

Leave a Reply

Your email address will not be published.